- Home
- CLLS vs SOPH Comparison
CLLS vs SOPH Comparison
Compare CLLS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | SOPH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.6M | 330.4M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | SOPH |
|---|---|---|
| Price | $4.75 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.50 | $7.00 |
| AVG Volume (30 Days) | ★ 112.6K | 75.4K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $82,551,000.00 | $73,297,000.00 |
| Revenue This Year | $32.58 | $18.32 |
| Revenue Next Year | $20.68 | $15.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | 13.66 |
| 52 Week Low | $1.10 | $2.58 |
| 52 Week High | $5.48 | $5.30 |
Technical Indicators
Market Signals| Indicator | CLLS | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 52.12 |
| Support Level | $4.47 | $4.50 |
| Resistance Level | $5.03 | $4.84 |
| Average True Range (ATR) | 0.28 | 0.22 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 54.55 | 48.00 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.